IL282854B - Treatment and prevention of fibrosis in patients with non-alcoholic fatty liver disease - Google Patents

Treatment and prevention of fibrosis in patients with non-alcoholic fatty liver disease

Info

Publication number
IL282854B
IL282854B IL282854A IL28285421A IL282854B IL 282854 B IL282854 B IL 282854B IL 282854 A IL282854 A IL 282854A IL 28285421 A IL28285421 A IL 28285421A IL 282854 B IL282854 B IL 282854B
Authority
IL
Israel
Prior art keywords
fibrosis
inhibition
treatment
liver disease
fatty liver
Prior art date
Application number
IL282854A
Other languages
English (en)
Hebrew (he)
Other versions
IL282854A (en
Inventor
Hayardeny-Nisimov Liat
Tali Gorfine
Baharaff Allen
De La Paz Jose M Mato
Original Assignee
Galmed Res And Development Ltd
Liat Hayardeny Nisimov
Tali Gorfine
Baharaff Allen
De La Paz Jose M Mato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/182,767 external-priority patent/US20190175619A1/en
Application filed by Galmed Res And Development Ltd, Liat Hayardeny Nisimov, Tali Gorfine, Baharaff Allen, De La Paz Jose M Mato filed Critical Galmed Res And Development Ltd
Publication of IL282854A publication Critical patent/IL282854A/en
Publication of IL282854B publication Critical patent/IL282854B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL282854A 2018-11-07 2021-05-02 Treatment and prevention of fibrosis in patients with non-alcoholic fatty liver disease IL282854B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/182,767 US20190175619A1 (en) 2016-11-10 2018-11-07 Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
PCT/IL2019/051121 WO2020095293A1 (en) 2018-11-07 2019-10-16 Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients

Publications (2)

Publication Number Publication Date
IL282854A IL282854A (en) 2021-06-30
IL282854B true IL282854B (en) 2021-12-01

Family

ID=70611747

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282854A IL282854B (en) 2018-11-07 2021-05-02 Treatment and prevention of fibrosis in patients with non-alcoholic fatty liver disease

Country Status (8)

Country Link
EP (1) EP3876945A4 (de)
CN (1) CN113301902A (de)
AU (1) AU2019376907B2 (de)
BR (1) BR112021008896A2 (de)
CA (1) CA3117958A1 (de)
IL (1) IL282854B (de)
MX (1) MX2021005420A (de)
WO (1) WO2020095293A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197870B2 (en) * 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
US20190175619A1 (en) * 2016-11-10 2019-06-13 Galmed Research And Development Ltd. Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
CA3152584C (en) * 2016-11-10 2024-02-13 Galmed Research And Development Ltd. Treatment for fibrosis

Also Published As

Publication number Publication date
EP3876945A4 (de) 2022-08-24
IL282854A (en) 2021-06-30
EP3876945A1 (de) 2021-09-15
CA3117958A1 (en) 2020-05-14
AU2019376907A1 (en) 2021-06-24
BR112021008896A2 (pt) 2021-08-10
CN113301902A (zh) 2021-08-24
WO2020095293A1 (en) 2020-05-14
MX2021005420A (es) 2021-09-10
AU2019376907B2 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
IL279161A (en) Active substances and methods of their use for the treatment of metabolic disorders and non-alcoholic fatty liver disease
IL273550A (en) Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the I148M variant of PNPLA3
IL275188A (en) Use of cyclic tripeptide to improve cellular energy metabolism
IL272869A (en) Non-invasive diagnosis of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and/or liver fibrosis
SG11202001111QA (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
IL289167A (en) The history of 2h-indazole and their use in the treatment of diseases
IL281445A (en) Therapeutic nanoparticles and methods for their use
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA202007834B (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
ES3066079T3 (en) Uses of cyp4v2 and rdcvf in preparation of drugs
IL310132B2 (en) Methods of treatment and prevention of alzheimer's disease
IL268502A (en) Triple combination preparations and methods for treating heart disease or reducing its risk
EP3781158A4 (de) Zusammensetzungen zur behandlung von nicht-alkoholischer fettlebererkrankung und nicht-alkoholischer steatohepatitis
HUE071625T2 (hu) Pemafibrát SGLT2-gátlóval kombinációban, ami májbetegségek, zsírmáj profilaktikus vagy terápiás kezelésére szolgál
IL265292A (en) Medicinal compound and method for treating non-alcoholic fatty liver disease
IL275925A (en) Prevention and treatment of organ damage
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL285776A (en) Useful preparations in the treatment of Kraba's disease
IL282854A (en) Treatment and prevention of fibrosis in patients with non-alcoholic fatty liver disease
PT3595660T (pt) Compostos para utilização na prevenção e/ou tratamento de doença do fígado gordo não-alcoólico e esteato-hepatite nãoalcoólica
PT3723782T (pt) Péptidos para o tratamento e a prevenção de doença do fígado gordo não alcoólico
HK40047104A (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
HK40036137A (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease
GB201906597D0 (en) Treatment and prevention of metabolic diseases
HK40079252A (en) Treatment of non-alcoholic fatty liver disease